ArticleInternational journal of women's health2026
Trends, Risk Factors, and Future Burden of Female Breast Cancer in China and Other G20 Countries, 1990-2050: A Comparative Global Burden of Disease 2023 Analysis.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study analyzes the burden of female breast cancer in China and other G20 countries from 1990 to 2023, characterizes its trends and risk factors, and projects the burden to 2050. Methods: Using Global Burden of Disease (GBD) 2023 estimates, we evaluated age-standardized rates of incidence, mortality, and disability-adjusted life years (DALYs), the mortality-to-incidence ratio (MIR), and trends (estimated annual percentage change, EAPC); applied Das Gupta decomposition, sociodemographic index (SDI) gradient, attributable-risk, and socioeconomic-inequality analyses, with stratification by premenopausal (20-54 years) and postmenopausal (≥55 years) age groups; and used autoregressive integrated moving average (ARIMA) models to forecast to 2050. Results: In 2023, China's age-standardized incidence rate (ASIR) was 31.6 per 100,000, the second lowest among G20 members (range: India 29.4 to France 114.6), yet China recorded the largest absolute burden (342,725 cases and 76,589 deaths). Between 1990 and 2023, China's age-standardized mortality rate (ASMR) declined far more rapidly than in the rest of the G20 (EAPC -1.92 vs -0.23), whereas its ASIR rose only modestly (EAPC 0.40 vs 1.05); China's MIR fell to the eighth lowest by 2023. Across members, SDI correlated positively with ASIR ( Conclusions: Across the G20, female breast-cancer burden is undergoing an epidemiological transition: absolute burden is rising as populations grow and age, while age-standardized mortality is declining in most members, with marked heterogeneity across the G20. The burden is shifting toward older women in the postmenopausal age group, while the mortality-to-incidence ratio remains higher in lower-SDI members. These patterns argue for G20-coordinated, equity-focused prevention and survival care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.